Suresh Senan
MD PhD
Professor
👥Biography 个人简介
Suresh Senan has contributed to stereotactic ablative radiotherapy (SABR/SBRT) and its combination with immunotherapy. The PACIFIC trial established durvalumab after concurrent chemoradiation for unresectable stage III NSCLC as a new standard, significantly improving survival. His work on SABR-COMET exploring SABR for oligometastatic disease and on the immunological basis of the abscopal effect (immune response triggered at sites distant from irradiated tumor) has been important for radiation-immunotherapy combinations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Suresh Senan 的研究动态
Follow Suresh Senan's research updates
留下邮箱，当我们发布与 Suresh Senan（Amsterdam UMC）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment